On Friday 7 May, the European Medicines Agency (EMA) announced that it had started a rolling review of a new treatment for Covid-19.Sotrovimab is a monoclonal antibody treatment also known as VIR-7831 and GSK4182136, which was developed by the British pharmaceutical giant GSK and the American company Vir Biotechnology Inc.
This decision was based on preliminary results of a study on the drug’s ability to prevent hospitalisation or death in non-hospitalised patients with the virus, the...